PI3K/Akt信号通路在乳腺癌内分泌治疗耐药中的作用及对策  

The Role and Application of the PI3K/Akt Signaling Pathway in Breast Cancer with Endocrine Therapy Resistance

作　　者：林阳[1] 章斌[1] 

机构地区：[1]苏州大学附属第一医院核医学科,江苏苏州215006

出　　处：《标记免疫分析与临床》2015年第12期1287-1292,共6页Labeled Immunoassays and Clinical Medicine

基　　金：苏州市科技发展计划项目;项目编号:SYS201458

摘　　要：乳腺癌是女性最常见的肿瘤,大约75%的乳腺癌表达雌激素受体和/或孕激素受体。激素受体阳性的转移性乳腺癌患者通常采用内分泌治疗,然而由于内分泌治疗耐药的产生,其应用受到了限制。近年来发现,PI3K/Akt(丝氨酸/苏氨酸激酶)信号通路在乳腺癌的发展中发挥着重要作用。本文对PI3K/Akt信号通路在乳腺癌内分泌治疗耐药中的作用进行了综述,以期为雌激素受体阳性乳腺癌治疗提供新对策。Breast cancer is the most common cancer among women, about 75% of breast cancers express the estrogen receptor and/or the progesterone receptor. Patients with hormone receptor-positive metastatic breast cancer are usually treated with endocrine therapy. However, due to the generation of endocrine therapy resistance, its application has been limited. Recently discovered, PI3K/Akt signaling pathway plays an important role in the development of breast cancer. In this paper, we specifically analyze the role of the PI3K/Akt signaling pathway in breast cancer endocrine therapy resistance, in order to offer new strategies to estrogen receptor-positive breast cancer.

关 键 词：乳腺癌 PI3K/AKT信号通路 内分泌治疗耐药 PI3K/Akt通路抑制剂 联合治疗 

分 类 号：R737.9[医药卫生—肿瘤]